Pharma BD Deal Intelligence
AstraZeneca acquired Icosavax for $1.1B for RSV vaccine development.
AstraZeneca will pay up to $1.1B to acquire Icosavax, a University of Washington biotech spinout developing VLP vaccines
AstraZeneca completes Icosavax acquisition for $1.1bn, gaining RSV and hMPV combination vaccine candidate IVX-A12
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca acquired Icosavax for up to $1.1B ($800M upfront plus a contingent value right of up to ~$5/share) to add IVX-A12, a bivalent protein virus-like-particle vaccine candidate targeting RSV and human metapneumovirus (hMPV) in older adults. The deal closed in February 2024. As of late 2025, the IVX-A12 Phase 2 program had completed (NCT05903183, NCT06481579) but no Phase 3 trial had been publicly registered, so the 'Phase III-ready' asset that underpinned the acquisition had not yet visibly advanced to pivotal development.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Icosavax Inc. (this deal) | 2023 | $1.1B | 61 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Infectious Disease deals